Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890529612> ?p ?o ?g. }
- W2890529612 abstract "Approximately 40% to 95% of people with cirrhosis have oesophageal varices. About 15% to 20% of oesophageal varices bleed in about one to three years. There are several different treatments to prevent bleeding, including: beta-blockers, endoscopic sclerotherapy, and variceal band ligation. However, there is uncertainty surrounding their individual and relative benefits and harms.To compare the benefits and harms of different treatments for prevention of first variceal bleeding from oesophageal varices in adults with liver cirrhosis through a network meta-analysis and to generate rankings of the different treatments for prevention of first variceal bleeding from oesophageal varices according to their safety and efficacy.We searched CENTRAL, MEDLINE, Embase, Science Citation Index Expanded, World Health Organization International Clinical Trials Registry Platform, and trials registers to December 2019 to identify randomised clinical trials in people with cirrhosis and oesophageal varices with no history of bleeding.We included only randomised clinical trials (irrespective of language, blinding, or status) in adults with cirrhosis and oesophageal varices with no history of bleeding. We excluded randomised clinical trials in which participants had previous bleeding from oesophageal varices and those who had previously undergone liver transplantation or previously received prophylactic treatment for oesophageal varices.We performed a network meta-analysis with OpenBUGS using Bayesian methods and calculated the differences in treatments using hazard ratios (HR), odds ratios (OR), and rate ratios with 95% credible intervals (CrI) based on an available-case analysis, according to National Institute for Health and Care Excellence Decision Support Unit guidance. We performed the direct comparisons from randomised clinical trials using the same codes and the same technical details.We included 66 randomised clinical trials (6653 participants) in the review. Sixty trials (6212 participants) provided data for one or more comparisons in the review. The trials that provided the information included people with cirrhosis due to varied aetiologies and those at high risk of bleeding from oesophageal varices. The follow-up in the trials that reported outcomes ranged from 6 months to 60 months. All but one of the trials were at high risk of bias. The interventions compared included beta-blockers, no active intervention, variceal band ligation, sclerotherapy, beta-blockers plus variceal band ligation, beta-blockers plus nitrates, nitrates, beta-blockers plus sclerotherapy, and portocaval shunt. Overall, 21.2% of participants who received non-selective beta-blockers ('beta-blockers') - the reference treatment (chosen because this was the most common treatment compared in the trials) - died during 8-month to 60-month follow-up. Based on low-certainty evidence, beta-blockers, variceal band ligation, sclerotherapy, and beta-blockers plus nitrates all had lower mortality versus no active intervention (beta-blockers: HR 0.49, 95% CrI 0.36 to 0.67; direct comparison HR: 0.59, 95% CrI 0.42 to 0.83; 10 trials, 1200 participants; variceal band ligation: HR 0.51, 95% CrI 0.35 to 0.74; direct comparison HR 0.49, 95% CrI 0.12 to 2.14; 3 trials, 355 participants; sclerotherapy: HR 0.66, 95% CrI 0.51 to 0.85; direct comparison HR 0.61, 95% CrI 0.41 to 0.90; 18 trials, 1666 participants; beta-blockers plus nitrates: HR 0.41, 95% CrI 0.20 to 0.85; no direct comparison). No trials reported health-related quality of life. Based on low-certainty evidence, variceal band ligation had a higher number of serious adverse events (number of events) than beta-blockers (rate ratio 10.49, 95% CrI 2.83 to 60.64; 1 trial, 168 participants). Based on low-certainty evidence, beta-blockers plus nitrates had a higher number of 'any adverse events (number of participants)' than beta-blockers alone (OR 3.41, 95% CrI 1.11 to 11.28; 1 trial, 57 participants). Based on low-certainty evidence, adverse events (number of events) were higher in sclerotherapy than in beta-blockers (rate ratio 2.49, 95% CrI 1.53 to 4.22; direct comparison rate ratio 2.47, 95% CrI 1.27 to 5.06; 2 trials, 90 participants), and in beta-blockers plus variceal band ligation than in beta-blockers (direct comparison rate ratio 1.72, 95% CrI 1.08 to 2.76; 1 trial, 140 participants). Based on low-certainty evidence, any variceal bleed was lower in beta-blockers plus variceal band ligation than in beta-blockers (direct comparison HR 0.21, 95% CrI 0.04 to 0.71; 1 trial, 173 participants). Based on low-certainty evidence, any variceal bleed was higher in nitrates than beta-blockers (direct comparison HR 6.40, 95% CrI 1.58 to 47.42; 1 trial, 52 participants). The evidence indicates considerable uncertainty about the effect of the interventions in the remaining comparisons.Based on low-certainty evidence, beta-blockers, variceal band ligation, sclerotherapy, and beta-blockers plus nitrates may decrease mortality compared to no intervention in people with high-risk oesophageal varices in people with cirrhosis and no previous history of bleeding. Based on low-certainty evidence, variceal band ligation may result in a higher number of serious adverse events than beta-blockers. The evidence indicates considerable uncertainty about the effect of beta-blockers versus variceal band ligation on variceal bleeding. The evidence also indicates considerable uncertainty about the effect of the interventions in most of the remaining comparisons." @default.
- W2890529612 created "2018-09-27" @default.
- W2890529612 creator A5003867336 @default.
- W2890529612 creator A5006371372 @default.
- W2890529612 creator A5009873146 @default.
- W2890529612 creator A5012191618 @default.
- W2890529612 creator A5015550514 @default.
- W2890529612 creator A5023563769 @default.
- W2890529612 creator A5024594304 @default.
- W2890529612 creator A5028509069 @default.
- W2890529612 creator A5044774436 @default.
- W2890529612 creator A5052400336 @default.
- W2890529612 creator A5054917523 @default.
- W2890529612 creator A5060216513 @default.
- W2890529612 creator A5062482983 @default.
- W2890529612 creator A5063029649 @default.
- W2890529612 creator A5065772246 @default.
- W2890529612 creator A5075723738 @default.
- W2890529612 creator A5079079428 @default.
- W2890529612 creator A5085782112 @default.
- W2890529612 creator A5087707746 @default.
- W2890529612 date "2021-04-06" @default.
- W2890529612 modified "2023-09-26" @default.
- W2890529612 title "Primary prevention of variceal bleeding in people with oesophageal varices due to liver cirrhosis: a network meta-analysis" @default.
- W2890529612 cites W1444900349 @default.
- W2890529612 cites W1482298482 @default.
- W2890529612 cites W1490907837 @default.
- W2890529612 cites W1498357895 @default.
- W2890529612 cites W1505560760 @default.
- W2890529612 cites W1517710152 @default.
- W2890529612 cites W1534719948 @default.
- W2890529612 cites W1546359130 @default.
- W2890529612 cites W1552630832 @default.
- W2890529612 cites W1554641506 @default.
- W2890529612 cites W1591632796 @default.
- W2890529612 cites W1593043915 @default.
- W2890529612 cites W161054682 @default.
- W2890529612 cites W1617328014 @default.
- W2890529612 cites W163576887 @default.
- W2890529612 cites W170226017 @default.
- W2890529612 cites W1770014952 @default.
- W2890529612 cites W184308473 @default.
- W2890529612 cites W1896059571 @default.
- W2890529612 cites W1899099619 @default.
- W2890529612 cites W1937469442 @default.
- W2890529612 cites W1957005022 @default.
- W2890529612 cites W1957607057 @default.
- W2890529612 cites W1963531850 @default.
- W2890529612 cites W1964489041 @default.
- W2890529612 cites W1964502734 @default.
- W2890529612 cites W1965295467 @default.
- W2890529612 cites W1967218527 @default.
- W2890529612 cites W1967522559 @default.
- W2890529612 cites W1968239929 @default.
- W2890529612 cites W1970464054 @default.
- W2890529612 cites W1970752949 @default.
- W2890529612 cites W1971895240 @default.
- W2890529612 cites W1972019808 @default.
- W2890529612 cites W1973164007 @default.
- W2890529612 cites W1975776831 @default.
- W2890529612 cites W1976442249 @default.
- W2890529612 cites W1978055496 @default.
- W2890529612 cites W1979286248 @default.
- W2890529612 cites W1980665963 @default.
- W2890529612 cites W1980734258 @default.
- W2890529612 cites W1980831697 @default.
- W2890529612 cites W1981180602 @default.
- W2890529612 cites W1983160686 @default.
- W2890529612 cites W1984942504 @default.
- W2890529612 cites W1985612238 @default.
- W2890529612 cites W1985963090 @default.
- W2890529612 cites W1987305426 @default.
- W2890529612 cites W1987530799 @default.
- W2890529612 cites W1989831468 @default.
- W2890529612 cites W1990693343 @default.
- W2890529612 cites W1990960937 @default.
- W2890529612 cites W1992250826 @default.
- W2890529612 cites W1995381612 @default.
- W2890529612 cites W1995932670 @default.
- W2890529612 cites W1996152976 @default.
- W2890529612 cites W1996483456 @default.
- W2890529612 cites W1997213113 @default.
- W2890529612 cites W1998576210 @default.
- W2890529612 cites W1998860493 @default.
- W2890529612 cites W1999611380 @default.
- W2890529612 cites W2004205220 @default.
- W2890529612 cites W2004972926 @default.
- W2890529612 cites W2005233497 @default.
- W2890529612 cites W2005770949 @default.
- W2890529612 cites W2006584180 @default.
- W2890529612 cites W2007083511 @default.
- W2890529612 cites W2007677328 @default.
- W2890529612 cites W2009177756 @default.
- W2890529612 cites W2009399272 @default.
- W2890529612 cites W2010551207 @default.
- W2890529612 cites W2010699829 @default.
- W2890529612 cites W2011932878 @default.
- W2890529612 cites W2012755580 @default.
- W2890529612 cites W2012829259 @default.
- W2890529612 cites W2013499640 @default.